Drug interactions
Doxorubicin + Givosiran
Severity: Minor
Doxorubicin and Givosiran: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Givosiran can raise exposure to CYP2D6 substrates, but CYP2D6 is a minor pathway for doxorubicin, so a meaningful clinical effect is unlikely.
What this interaction means in plain words
Doxorubicin and Givosiran have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Doxorubicin belongs to Oncology; Givosiran belongs to Miscellaneous.
Why it happens
Givosiran reduces CYP2D6 activity, which plays only a minor role in doxorubicin metabolism.
What to do
No dose change is generally needed. Monitor for usual doxorubicin toxicity.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Doxorubicin and Givosiran, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Doxorubicin
Other interactions of Givosiran
- Duloxetine + Givosiran Major
- Givosiran + Pimozide Major
- Givosiran + Propafenone Major
- Givosiran + Theophylline Major
- Givosiran + Thioridazine Major
- Givosiran + Tizanidine Major
Frequently asked questions
Can I take Doxorubicin with Givosiran?
MediHelp rates the interaction as minor. Doxorubicin and Givosiran have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Givosiran can raise exposure to CYP2D6 substrates, but CYP2D6 is a minor pathway for doxorubicin, so a meaningful clinical effect is unlikely.
How serious is the interaction between Doxorubicin and Givosiran?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is generally needed. Monitor for usual doxorubicin toxicity.
What other medicines interact with Doxorubicin?
MediHelp also lists interactions of Doxorubicin with, for example, Adenovirus types 4 and 7 live, Belatacept, Cobicistat. The full list is on the Doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
